GleamWall
中文EN

LGND LIGAND PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 886163 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.0%
TTM net income YoY5.9%
TTM EPS YoY9.7%
Revenue 3-yr CAGR18.2%
Net income 3-yr CAGR46.2%

Margins

Gross margin—
Operating margin9.5%
Net margin20.3%
FCF margin35.7%
EBITDA margin23.2%

Returns

ROE5.4%
ROA2.8%
ROIC (approx.)1.4%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets57.0%
Debt / equity1.17x
Current ratio1.22x
Interest coverage2.94x

Cash quality & payout

Operating cash flow / net income1.77x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$78.75M$63.69M$51.72M$59.67M$115.46M$47.63M$45.33M$42.81M
R&D expense$2.77M$14.67M$2.15M$3.51M$21.02M$6.57M$50.09M$4.42M
SG&A expense$72.62M$29.12M$20.84M$25.03M$28.45M$20.18M$18.80M$25.61M
Operating income-$15.76M$8.59M$17.37M$13.84M$55.39M$8.44M-$36.22M-$9.64M
Interest expense$2.90M$1.75M$1.75M$1.78M$910,000$1.15M$867,000$883,000
Pretax income-$44.09M$64.30M-$24.26M$56.78M$141.14M$11.22M-$50.18M-$39.20M
Income tax-$15.61M$15.80M-$10.91M$12.00M$23.86M$6.38M-$7.73M-$8.11M
Net income-$28.48M$48.51M-$13.35M$44.78M$117.27M$4.85M-$42.45M-$31.09M
EBITDA-$5.43M$16.81M$25.58M$22.06M$63.66M$16.97M-$27.45M-$1.01M
EPS (basic)-1.432.42-0.67—5.990.25-2.21—
EPS (diluted)-1.432.22-0.67—5.680.24-2.21—
Weighted avg. shares (diluted)19.96M21.84M19.88M—20.63M19.93M19.19M—
Balance sheet
Cash & equivalents$55.96M$1.01B$115.08M$174.93M$139.38M$67.67M$47.99M$72.31M
Short-term investments$391.44M$351.06M$664.33M$558.59M$525.15M$177.35M$160.91M$183.86M
Receivables$83.22M$67.01M$53.38M$59.60M$57.56M$41.29M$38.49M$38.38M
Inventory$14.51M$10.26M$13.27M$9.13M$11.90M$15.49M$14.61M$14.11M
Current assets$608.23M$1.46B$865.41M$832.27M$753.92M$352.94M$309.32M$331.56M
PP&E, net$3.71M$3.40M$3.44M$3.57M$3.47M$3.63M$3.62M$15.13M
Goodwill$207.86M$101.54M$101.54M$101.54M$101.54M$101.54M$101.54M$105.25M
Intangibles$302.04M$209.24M$217.34M$225.44M$233.53M$250.13M$258.39M$266.65M
Total assets$2.24B$2.19B$1.53B$1.56B$1.48B$948.60M$905.43M$941.77M
Current liabilities$500.57M$46.74M$40.67M$37.45M$30.54M$64.73M$58.68M$37.11M
Short-term debt$448.31M———————
Long-term debt$679.91M$1.13B$446.90M$446.19M$445.49M——$0
Total debt$1.13B$1.13B$446.90M$446.19M$445.49M——$0
Total liabilities$1.28B$1.22B$534.78M$543.42M$526.60M$120.08M$109.90M$111.33M
Shareholders' equity$961.76M$967.52M$997.32M$1.02B$950.17M$827.31M$795.59M$830.44M
Net debt$1.07B$119.89M$331.82M$271.26M$306.12M——-$72.31M
Shares outstanding20.00M19.92M20.03M19.77M19.66M19.41M19.28M19.11M
Cash flow statement
Operating cash flow-$27.59M$24.02M$48.69M$45.91M$13.09M$15.80M-$25.45M$28.47M
Capital expenditure$142,000$26,000$228,000$9,000$15,000$214,000$214,000$712,000
Free cash flow-$27.73M$23.99M$48.46M$45.91M$13.07M$15.59M-$25.66M$27.76M
Investing cash flow-$877.99M$321.12M-$94.35M-$18.10M-$353.44M-$10.67M$4.89M-$38.62M
Financing cash flow$4.06M$546.43M-$14.13M$8.33M$409.64M$14.99M-$4.75M$20.39M
Depreciation & amortization$10.32M$8.21M$8.22M$8.21M$8.27M$8.52M$8.77M$8.63M
Stock-based compensation$18.18M$13.65M$10.60M$14.27M$14.75M$10.00M$7.84M$7.52M
Share buybacks$0——$0$15.00M——$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.